As part of the reprioritization, SAGE will focus on the commercialization of its depression drug Zurzuvae (zuranolone), which ...
1d
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...
Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...
US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce.
Sage Therapeutics announces a reorganization to support product launch and pipeline development, resulting in a workforce ...
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...
After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...
Sage and Biogen last year won Food and Drug Administration approval of Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major depressive disorder, a much ...
Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 ...
The FDA approved Zurzuvae as the first oral therapy for post-partum depression (PPD) in August 2023, although, the agency ...
MarketWatch on MSN1d
Sage Therapeutics’ stock falls 4.7% as biotech unveils plan to cut 33% of workforceSage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...
Talkiatry partnership resembles efforts by pharma companies like Eli Lilly and Pfizer to team up with telehealth companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback